The latency between previous cancer treatment and leukemia development is longer after alkylating agents
(3-8 years) and shorter after topoisomerase II inhibitors (2-3 years).
This would include patients diagnosed with cancers known to require exposure to known gonadotoxic agents (such as high doses of alkylating agents
, as seen in cases of rhabdomyosarcoma, Ewing's sarcoma, neuroblastoma, Hodgkin's lymphoma) or radiation to achieve cure (e.
25) However, both alkylating agents
are associated with serious side effects such as anaemia, teratogenicity, thrombocytopenia, infertility, infection, and in the case of cyclophosphamide, the development of secondary malignancies.
Antimetabolites, T-Cell Inhibitors and Alkylating Agents
Radiotherapy, alkylating agents
, and risk of bone cancer after childhood cancer," Journal of the National Cancer Institute, vol.
It was reported yesterday that the contract has been signed to develop structurally new generation alkylating agents
to treat haematological malignancies.
Our study showed that these alkylating agents
are present at levels sufficient to cause DNA damage and could potentially have adverse implications to human health, particularly in the case of the development of oral cancer for BQ chewers," they said.
reported that patients treated with alkylating agents
had fewer primordial follicles in their ovaries than those that were not treated with these agents (8).
In general the alkylating agents
interact with DNA, preventing replication and/or transcription.
Synthesis of quinonemethide, its reactivity and electrochemistry of purine-like imidazo[4,5-g]quinazoline reductive alkylating agents
possessing a leaving group at the 6a-position were studied.
Men treated with alkylating agents
, which are commonly used to treat lymphomas and sarcomas, had the lowest retrieval rates (33% success for lymphomas).
that bond covalently to the cellular DNA to inhibit its replication